Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

tad pharma gmbh - escitalopram oxalato - comprimido recubierto con pelÍcula - 15 mg - escitalopram oxalato 15 mg - escitalopram

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mcm pharma gmbh - acido zoledronico - concentrado para soluciÓn para perfusiÓn - 0,8 mg/ml inyectable 5 ml - acido zoledronico 0.8 mg - Ácido zoledrónico

Evrópusambandið - spænska - EMA (European Medicines Agency)

sandoz gmbh - pregabalina - anxiety disorders; epilepsy - los antiepilépticos, - epilepsypregabalin sandoz gmbh está indicado como terapia adyuvante en pacientes adultos con crisis parciales con o sin generalización secundaria. de ansiedad generalizada disorderpregabalin sandoz gmbh está indicado para el tratamiento del trastorno de ansiedad generalizada (tag) en adultos.

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

g.l. pharma gmbh - metoxaleno - soluciÓn para modificaciÓn de las fracciones sanguÍneas - 20 microgramos/ml - metoxaleno 20 microgramos - otros inmunoestimulantes

Evrópusambandið - spænska - EMA (European Medicines Agency)

taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

tad pharma gmbh - paliperidona - comprimido de liberaciÓn prolongada - 3 mg - paliperidona 3 mg - paliperidona

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

tad pharma gmbh - paliperidona - comprimido de liberaciÓn prolongada - 6 mg - paliperidona 6 mg - paliperidona

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

tad pharma gmbh - paliperidona - comprimido de liberaciÓn prolongada - 9 mg - paliperidona 9 mg - paliperidona

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

tad pharma gmbh - lacosamida - comprimido recubierto con pelÍcula - 50 mg - lacosamida 50 mg - lacosamida

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

tad pharma gmbh - lacosamida - comprimido recubierto con pelÍcula - 100 mg - lacosamida 100 mg - lacosamida